Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Infinity Begins Chondrosarcoma Trial

March 3, 2011 6:54 am | News | Comments

Infinity Pharmaceuticals, Inc. announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo in patients with metastatic or locally advanced, inoperable chondrosarcoma.

TOPICS:

DURATION-6 Study Results Released

March 3, 2011 6:48 am | News | Comments

Amylin Pharmaceuticals, Inc., Eli Lilly and Company, and Alkermes, Inc. announced top-line results from DURATION-6, a head-to-head study designed to compare weekly BYDUREON, an investigational type 2 diabetes therapy, to daily Victoza.

TOPICS:

Virtual Slide System

March 2, 2011 6:27 am | Product Releases | Comments

The VS800 virtual slide system from Olympus allows researchers to scan and review microscope slides in just minutes. The self-contained, eyepiece-free system offers customized proprietary Olympus optics for the highest quality scans.

TOPICS:
Advertisement

Interferon ELISA Kit

March 2, 2011 6:22 am | Product Releases | Comments

PBL InterferonSource has launched the VeriPlex Human Interferon Multiplex ELISA kit, which allows simultaneous quantifying of Human Type I, II, and III interferons as well as related pro-inflammatory cytokines from a single biological sample.

TOPICS:

VaxInnate Wins $196M Flu Contract

March 2, 2011 6:05 am | News | Comments

VaxInnate Corporation announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines.

TOPICS:

ACT Files SPA with FDA

March 2, 2011 5:59 am | News | Comments

ACT Biotech, Inc. has filed a special protocol assessment with the U.S. Food and Drug Administration related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer.

TOPICS:

Study Links Vitamin D to Lung Cancer Survival

March 2, 2011 5:56 am | News | Comments

Recent research suggests vitamin D may be able to stop or prevent cancer. Now, a new study finds an enzyme that plays a role in metabolizing vitamin D can predict lung cancer survival.

TOPICS:

New Findings on Drug Delivery with Nanoparticles

March 2, 2011 5:54 am | News | Comments

Researchers have shown that medicine designed at nanoscale offers unprecedented opportunities for targeted treatment of serious diseases such as cancer. However, research also shows that the body's immune system plays a part in the drug delivery process.

TOPICS:
Advertisement

Merck Receives CRL for Cladribine

March 2, 2011 5:50 am | News | Comments

Merck KGaA has received a complete response letter from the U.S. Food and Drug Administration on the new drug application for Cladribine Tablets, its investigational oral formulation of cladribine, a therapy for relapsing-remitting multiple sclerosis.

TOPICS:

FDA Approves Takeda's Edarbi

March 2, 2011 5:47 am | News | Comments

The U.S. Food and Drug Administration approved Edarbi tablets to treat high blood pressure in adults. Data from clinical studies showed Edarbi to be more effective in lowering 24-hour blood pressure compared with two other FDA-approved hypertension drugs.

TOPICS:

BMS R & D Head Joins Board

March 2, 2011 5:44 am | News | Comments

The drugmaker Bristol-Myers Squibb Co. said that Elliott Sigal he been elected to its board of directors. Sigal, 59, is the company's chief scientific officer and the president of its research and development unit.

TOPICS:

Indians Protest Pharmaceutical Trade Deal

March 2, 2011 5:42 am | News | Comments

More than 2,000 HIV-positive people from India and other Asian nations marched in New Delhi to demand the Indian government reject provisions on pharmaceuticals in the India-European Union free trade agreement.

TOPICS:

GTx-Ipsen End Toremifene Partnership

March 2, 2011 5:38 am | News | Comments

GTx Inc. said it is ending a development deal with drug maker Ipsen Ltd. over the bone drug toremifene. The drug is designed to reduce bone fractures in men who have prostate cancer and are being treated with androgen deprivation therapy.

TOPICS:

Mylan Estrogen Patch Triggers Lawsuits

March 2, 2011 5:36 am | News | Comments

Mylan Inc. said that it asked the Food and Drug Administration to approve a generic version of Noven Pharmaceuticals Inc.'s Vivelle-Dot estrogen patch, prompting patent lawsuits.

TOPICS:

Nektar Move Hits Bottom Line

March 2, 2011 5:33 am | News | Comments

Biotechnology company Nektar Therapeutics reported a larger fourth-quarter loss as it moved to a new research and development facility. The company said it lost $22.6 million, or 24 cents per share.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading